BI 754132
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
August 24, 2022
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=18 | Terminated | Sponsor: Boehringer Ingelheim | N=30 ➔ 18 | Suspended ➔ Terminated; The trial was discontinued in the interests of patients considering benefit/risk balance.
Enrollment change • Trial termination • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
July 12, 2022
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=30 | Suspended | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2022 ➔ Aug 2022 | Trial primary completion date: Nov 2022 ➔ Aug 2022
Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
April 28, 2022
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=30 | Suspended | Sponsor: Boehringer Ingelheim | Recruiting ➔ Suspended
Trial suspension • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
November 04, 2021
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Jun 2022 ➔ Nov 2022; Trial primary completion date: Jun 2022 ➔ Nov 2022
Clinical • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
June 02, 2021
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; Trial primary completion date: Mar 2022 ➔ Jun 2022
Clinical • Trial primary completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
January 28, 2021
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; N=18 ➔ 24
Clinical • Enrollment change • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
July 02, 2020
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Mar 2022 ➔ Jun 2022
Clinical • Trial completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders
May 27, 2020
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Suspended ➔ Recruiting; Trial completion date: Apr 2021 ➔ Mar 2022; Trial primary completion date: Apr 2021 ➔ Mar 2022
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders
April 07, 2020
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Suspended; Sponsor: Boehringer Ingelheim; Trial completion date: Jan 2021 ➔ Apr 2021; Recruiting ➔ Suspended
Trial completion date • Trial suspension
November 15, 2019
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Jun 2020 ➔ Oct 2020; Trial primary completion date: Jun 2020 ➔ Oct 2020
Clinical • Trial completion date • Trial primary completion date
July 31, 2019
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
1 to 11
Of
11
Go to page
1